Stockreport

https://seekingalpha.com/article/4761382-summit-therapeutics-mid-2025-nsclc-data-could-further-entrench-ivonescimab-program [Seeking Alpha]

Summit Therapeutics Inc.  (SMMT) 
Last summit therapeutics inc. earnings: 6/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: summitplc.com/investors/investor-centre
PDF Top-line data from the phase 3 HARMONi study, using ivonescimab +chemotherapy to target 2nd-line EGFR-mutant NSCLC patients, expected in mid-2025. The global non-smal [Read more]